Neuroprotection in parkinson's disease: A realistic goal?

CNS Neuroscience and Therapeutics

Volumn 16, Issue 6, 2010, Pages 327-329

  Galati, Salvatore ^a   Di Giovanni, Giuseppe ^b,c  

^a Ospedale Civico Lugano   (Switzerland)

^b CARDIFF UNIVERSITY   (United Kingdom)

^c UNIVERSITY OF MALTA   (Malta)

Author keywords

[No Author keywords available]

Indexed keywords

DOPAMINE;

DISEASE COURSE; DOPAMINERGIC ACTIVITY; EDITORIAL; EXCITOTOXICITY; HUMAN; NERVE CELL NECROSIS; NEUROPROTECTION; NONHUMAN; PARKINSON DISEASE; PATHOGENESIS; PROTEIN AGGREGATION; SUBSTANTIA NIGRA;

ANIMALS; BIOLOGICAL MARKERS; DISEASE MODELS, ANIMAL; DISEASE PROGRESSION; DOPAMINE; HUMANS; NEUROLOGY; NEUROPROTECTIVE AGENTS; PARKINSON DISEASE;

EID: 78649246568     PISSN: 17555930     EISSN: 17555949     Source Type: Journal    
DOI: 10.1111/j.1755-5949.2010.00206.x     Document Type: Editorial

References (32)

1. Kincses ZT, Vecsei L,. Pharmacological therapy in parkinson's disease: Focus on neuroprotection. CNS Neurosci Ther 2010. doi
2. Ehringer H, Hornykiewicz O,. Verteilung von noradrenalin und dopamin (3-Hydroxytyramin) im Gehirn desMenshen und ihr verhalten bei erkrankungen des extrapyramidalen systems. Klin Wschr 1960; 38: 1236 - 1239.
3. Di Giovanni G,. Will it be possible to prevent nigral neurodegeneration? CNS Neurol Disord Drug Targets 2008; 7: 28 - 44.
4. Schulz JB,. Mechanisms of neurodegeneration in idiopathic Parkinson's disease. Parkinsonism Relat Disord 2007; 13 (Suppl 3): S306 - S308.
5. Di Giovanni G, Di Matteo V, Esposito E,. Death in the substantia nigra: A motor tragedy. Expert Rev Neurother 2007; 7: 677 - 697.
6. Beal MF,. Mitochondria, oxidative damage, and inflammation in Parkinson's disease. Ann N Y Acad Sci 2003; 991: 120 - 131.
7. Langston JW, Ballard P, Tetrud JW, Irwin I,. Chronic Parkinsonism in humans due to a product of meperidine-analog synthesis. Science 1983; 219: 979 - 980.
8. Elbaz A, Moisan F,. Update in the epidemiology of Parkinson's disease. Curr Opin Neurol 2008; 21: 454 - 460.
9. Windisch M, Wolf H, Hutter-Paier B, Wronski R,. The role of alpha-synuclein in neurodegenerative diseases: A potential target for new treatment strategies? Neurodegener Dis 2008; 5: 218 - 221.
10. Gautier CA, Kitada T, Shen J,. Loss of PINK1 causes mitochondrial functional defects and increased sensitivity to oxidative stress. Proc Natl Acad Sci USA 2008; 105: 11364 - 11369.
11. Iaccarino C, Crosio C, Vitale C, et al,. Apoptotic mechanisms in mutant LRRK2-mediated cell death. Hum Mol Genet 2007; 16: 1319 - 1326.
12. Fearnley JM, Lees AJ,. Ageing and Parkinson's disease: Substantia nigra regional selectivity. Brain 1991; 114 (Pt 5): 2283 - 2301.
13. Ross GW, Petrovitch H, Abbott RD, et al,. Parkinsonian signs and substantia nigra neuron density in decendents elders without PD. Ann Neurol 2004; 56: 532 - 539.
14. Greffard S, Verny M, Bonnet AM, et al,. Motor score of the Unified Parkinson Disease Rating Scale as a good predictor of Lewy body-associated neuronal loss in the substantia nigra. Arch Neurol 2006; 63: 584 - 588.
15. Abbott RD, Ross GW, Petrovitch H, et al,. Bowel movement frequency in late-life and incidental Lewy bodies. Mov Disord 2007; 22: 1581 - 1586.
16. Lees AJ,. The Parkinson chimera. Neurology 2009; 72 (Suppl 7): S2 - S11.
17. Braak H, Del Tredici K, Rub U, et al,. Staging of brain pathology related to sporadic Parkinson's disease. Neurobiol Aging 2003; 24: 197 - 211.
18. Olanow CW, Rascol O,. The delayed-start study in Parkinson disease: Can't satisfy everyone. Neurology 2010; 74: 1149 - 1150.
19. Ahlskog JE, Uitti RJ,. Rasagiline, Parkinson neuroprotection, and delayed-start trials: Still no satisfaction? Neurology 2010; 74: 1143 - 1148.
20. Olanow CW, Rascol O,. The delayed-start study in Parkinson disease: Can't satisfy everyone. Neurology 2010; 74: 1149 - 1150.
21. Parkinson Study Group. Dopamine transporter brain imaging to assess the effects of pramipexole vs levodopa on Parkinson disease progression. JAMA 2002; 287: 1653 - 1661.
22. Whone AL, Watts RL, Stoessl AJ, et al,. Slower progression of Parkinson's disease with ropinirole versus levodopa: The REAL-PET study. Ann Neurol 2003; 54: 93 - 101.
23. Ahlskog JE,. Slowing Parkinson's disease progression: Recent dopamine agonist trials. Neurology 2003; 60: 381 - 389.
24. Albin RL, Frey KA,. Initial agonist treatment of Parkinson's disease: A critique. Neurology 2003; 60: 390 - 394.
25. Maetzler W, Liepelt I, Berg D,. Progression of Parkinson's disease in the clinical phase: Potential markers. Lancet Neurol 2009; 8: 1158 - 1171.
26. Antoniades CA, Barker RA,. The search for biomarkers in Parkinson's disease: A critical review. Expert Rev Neurother 2008; 8: 1841 - 1852.
27. Pahwa R, Lyons KE,. Early diagnosis of Parkinson's disease: Recommendations from diagnostic clinical guidelines. Am J Manag Care 2010; 16: S94 - S99.
28. Piccini P, Pavese N,. Functional neuroimaging in movement disorders. In:, Di Giovanni G, editor. The Basal Ganglia Pathophysiology: Recent Advances. India: Transworld research Network, 2007.
29. Kägi G, Bhatia KP, Tolosa E,. The role of DAT-SPECT in movement disorders. J Neurol Neurosurg Psychiatry 2010; 81: 5 - 12.
30. Suchowersky O, Reich S, Perlmutter J, Zesiewicz T, Gronseth G, Weiner WJ,; Quality Standards Subcommittee of the American Academy of Neurology. Practice Parameter: diagnosis and prognosis of new onset Parkinson disease (an evidence-based review): Report of the Quality Standards Subcommittee of the American Academy of Neurology. Neurology 2006; 66: 968 - 975.
31. Berendse HW, Ponsen MM,. Diagnosing premotor Parkinson's disease using a two-step approach combining olfactory testing and DAT SPECT imaging. Parkinsonism Relat Disord 2009; 15 (Suppl 3): S26 - S30.
32. Di Giovanni G,. A diet for the dopaminergic neurons?. J Neural Transm Suppl 2009; 73, 317 - 332.